1
|
Dressler D, Bigalke H, Frevert J. The Immunology of Botulinum Toxin Therapy: A Brief Summary. Toxicology 2022; 481:153341. [PMID: 36191878 DOI: 10.1016/j.tox.2022.153341] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2022] [Revised: 09/13/2022] [Accepted: 09/27/2022] [Indexed: 11/28/2022]
Abstract
Like all proteins foreign to the human body, also botulinum toxin (BT) is antigenic and may stimulate an immune response with formulation of antibodies (BT-AB). Affected patients may no longer respond to BT therapy and various degrees of BT-AB related therapy failure (ABF) may result. We want to review the immunological interactions between BT and BT-AB, the prevalence, the time course and the risk factors for BT-AB formation as they are related to the treatment algorithms, the patient's immune system and to exogenic factors. Special emphasis is placed on various features of the BT drugs including the specific biological activity (SBA) as a predictor of their antigenicity. Quantitative detection of BT-AB by the mouse diaphragm assay will be demonstrated. As ABF may have serious consequences for patients affected, careful risk factor analysis is warranted to reduce them wherever possible.
Collapse
Affiliation(s)
- Dirk Dressler
- Movement Disorders Section, Department of Neurology, Hannover Medical School, Hannover, Germany.
| | - Hans Bigalke
- Institute of Toxicology, Hannover Medical School, Hannover, Germany.
| | | |
Collapse
|
2
|
Desplantes R, Lévêque C, Muller B, Lotierzo M, Ferracci G, Popoff M, Seagar M, Mamoun R, El Far O. Affinity biosensors using recombinant native membrane proteins displayed on exosomes: application to botulinum neurotoxin B receptor. Sci Rep 2017; 7:1032. [PMID: 28432329 PMCID: PMC5430821 DOI: 10.1038/s41598-017-01198-1] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2017] [Accepted: 03/27/2017] [Indexed: 12/31/2022] Open
Abstract
The development of simple molecular assays with membrane protein receptors in a native conformation still represents a challenging task. Exosomes are extracellular vesicles which, due to their stability and small size, are suited for analysis in various assay formats. Here, we describe a novel approach to sort recombinant fully native and functional membrane proteins to exosomes using a targeting peptide. Specific binding of high affinity ligands to the potassium channel Kv1.2, the G-protein coupled receptor CXCR4, and the botulinum neurotoxin type B (BoNT/B) receptor, indicated their correct assembly and outside out orientation in exosomes. We then developed, using a label-free optical biosensor, a new method to determine the kinetic constants of BoNT/B holotoxin binding to its receptor synaptotagmin2/GT1b ganglioside (kon = 2.3 ×105 M−1.s−1, koff = 1.3 10−4 s−1), yielding an affinity constant (KD = 0.6 nM) similar to values determined from native tissue. In addition, the recombinant binding domain of BoNT/B, a potential vector for neuronal delivery, bound quasi-irreversibly to synaptotagmin 2/GT1b exosomes. Engineered exosomes provide thus a novel means to study membrane proteins for biotechnology and clinical applications.
Collapse
Affiliation(s)
- Richard Desplantes
- INSERM, UMR_S 1072, 13015, Marseille, France.,Aix-Marseille Université, 13015, Marseille, France
| | - Christian Lévêque
- INSERM, UMR_S 1072, 13015, Marseille, France.,Aix-Marseille Université, 13015, Marseille, France
| | - Benjamin Muller
- Ciloa, cc90 - Université Montpellier 2, Place E. Bataillon, 34095, Montpellier Cedex 5, France
| | - Manuela Lotierzo
- Ciloa, cc90 - Université Montpellier 2, Place E. Bataillon, 34095, Montpellier Cedex 5, France
| | - Géraldine Ferracci
- Aix-Marseille Université, 13015, Marseille, France.,CNRS, UMR 7286, Plate-Forme de Recherche en Neurosciences PFRN, 13015, Marseille, France
| | - Michel Popoff
- CNR Anaérobies et botulisme, Unité Bactéries anaérobies et toxines. Institut Pasteur, 28 rue du Dr Roux, 75724, Paris, Cedex 15, France
| | - Michael Seagar
- INSERM, UMR_S 1072, 13015, Marseille, France.,Aix-Marseille Université, 13015, Marseille, France
| | - Robert Mamoun
- Ciloa, cc90 - Université Montpellier 2, Place E. Bataillon, 34095, Montpellier Cedex 5, France
| | - Oussama El Far
- INSERM, UMR_S 1072, 13015, Marseille, France. .,Aix-Marseille Université, 13015, Marseille, France.
| |
Collapse
|
3
|
Botulinum Neurotoxins: Qualitative and Quantitative Analysis Using the Mouse Phrenic Nerve Hemidiaphragm Assay (MPN). Toxins (Basel) 2015; 7:4895-905. [PMID: 26610569 PMCID: PMC4690105 DOI: 10.3390/toxins7124855] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2015] [Revised: 08/26/2015] [Accepted: 09/01/2015] [Indexed: 12/30/2022] Open
Abstract
The historical method for the detection of botulinum neurotoxin (BoNT) is represented by the mouse bioassay (MBA) measuring the animal survival rate. Since the endpoint of the MBA is the death of the mice due to paralysis of the respiratory muscle, an ex vivo animal replacement method, called mouse phrenic nerve (MPN) assay, employs the isolated N. phrenicus-hemidiaphragm tissue. Here, BoNT causes a dose-dependent characteristic decrease of the contraction amplitude of the indirectly stimulated muscle. Within the EQuATox BoNT proficiency 13 test samples were analysed using the MPN assay by serial dilution to a bath concentration resulting in a paralysis time within the range of calibration curves generated with BoNT/A, B and E standards, respectively. For serotype identification the diluted samples were pre-incubated with polyclonal anti-BoNT/A, B or E antitoxin or a combination of each. All 13 samples were qualitatively correctly identified thereby delivering superior results compared to single in vitro methods like LFA, ELISA and LC-MS/MS. Having characterized the BoNT serotype, the final bath concentrations were calculated using the calibration curves and then multiplied by the respective dilution factor to obtain the sample concentration. Depending on the source of the BoNT standards used, the quantitation of ten BoNT/A containing samples delivered a mean z-score of 7 and of three BoNT/B or BoNT/E containing samples z-scores <2, respectively.
Collapse
|
4
|
Koh CY, Schaff UY, Piccini M, Stanker L, Cheng LW, Ravichandran E, Singh BR, Sommer GJ, Singh AK. Centrifugal microfluidic platform for ultrasensitive detection of botulinum toxin. Anal Chem 2015; 87:922-8. [PMID: 25521812 PMCID: PMC4303339 DOI: 10.1021/ac504054u] [Citation(s) in RCA: 53] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2014] [Accepted: 12/17/2014] [Indexed: 02/06/2023]
Abstract
We present an innovative centrifugal microfluidic immunoassay platform (SpinDx) to address the urgent biodefense and public health need for ultrasensitive point-of-care/incident detection of botulinum toxin. The simple, sample-to-answer centrifugal microfluidic immunoassay approach is based on binding of toxins to antibody-laden capture particles followed by sedimentation of the particles through a density-media in a microfluidic disk and quantification by laser-induced fluorescence. A blind, head-to-head comparison study of SpinDx versus the gold-standard mouse bioassay demonstrates 100-fold improvement in sensitivity (limit of detection = 0.09 pg/mL), while achieving total sample-to-answer time of <30 min with 2-μL required volume of the unprocessed sample. We further demonstrate quantification of botulinum toxin in both exogeneous (human blood and serum spiked with toxins) and endogeneous (serum from mice intoxicated via oral, intranasal, and intravenous routes) samples. SpinDx can analyze, without any sample preparation, multiple sample types including whole blood, serum, and food. It is readily expandable to additional analytes as the assay reagents (i.e., the capture beads and detection antibodies) are disconnected from the disk architecture and the reader, facilitating rapid development of new assays. SpinDx can also serve as a general-purpose immunoassay platform applicable to diagnosis of other conditions and diseases.
Collapse
Affiliation(s)
- Chung-Yan Koh
- Sandia National
Laboratories, 7011 East Avenue, Livermore, California 94551, United States
| | - Ulrich Y. Schaff
- Sandia National
Laboratories, 7011 East Avenue, Livermore, California 94551, United States
| | - Matthew
E. Piccini
- Sandia National
Laboratories, 7011 East Avenue, Livermore, California 94551, United States
| | - Larry
H. Stanker
- Western Regional
Research Center, Foodborne Contaminants Research Unit, U.S. Department
of Agriculture − Agricultural Research Service, Albany, California 94710, United States
| | - Luisa W. Cheng
- Western Regional
Research Center, Foodborne Contaminants Research Unit, U.S. Department
of Agriculture − Agricultural Research Service, Albany, California 94710, United States
| | - Easwaran Ravichandran
- University
of Massachusetts Dartmouth, North
Dartmouth, Massachusetts 02747, United States
| | - Bal-Ram Singh
- University
of Massachusetts Dartmouth, North
Dartmouth, Massachusetts 02747, United States
| | - Greg J. Sommer
- Sandia National
Laboratories, 7011 East Avenue, Livermore, California 94551, United States
| | - Anup K. Singh
- Sandia National
Laboratories, 7011 East Avenue, Livermore, California 94551, United States
| |
Collapse
|
5
|
Botulinum neurotoxin serotype D is poorly effective in humans: An in vivo electrophysiological study. Clin Neurophysiol 2013; 124:999-1004. [DOI: 10.1016/j.clinph.2012.11.004] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2012] [Revised: 11/06/2012] [Accepted: 11/07/2012] [Indexed: 11/22/2022]
|
6
|
Pellett S. Progress in cell based assays for botulinum neurotoxin detection. Curr Top Microbiol Immunol 2013; 364:257-85. [PMID: 23239357 DOI: 10.1007/978-3-642-33570-9_12] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Botulinum neurotoxins (BoNTs) are the most potent human toxins known and the causative agent of botulism, and are widely used as valuable pharmaceuticals. The BoNTs are modular proteins consisting of a heavy chain and a light chain linked by a disulfide bond. Intoxication of neuronal cells by BoNTs is a multi-step process including specific cell binding, endocytosis, conformational change in the endosome, translocation of the enzymatic light chain into the cells cytosol, and SNARE target cleavage. The quantitative and reliable potency determination of fully functional BoNTs produced as active pharmaceutical ingredient (API) requires an assay that considers all steps in the intoxication pathway. The in vivo mouse bioassay has for years been the 'gold standard' assay used for this purpose, but it requires the use of large numbers of mice and thus causes associated costs and ethical concerns. Cell-based assays are currently the only in vitro alternative that detect fully functional BoNTs in a single assay and have been utilized for years for research purposes. Within the last 5 years, several cell-based BoNT detection assays have been developed that are able to quantitatively determine BoNT potency with similar or greater sensitivity than the mouse bioassay. These assays now offer an alternative method for BoNT potency determination. Such quantitative and reliable BoNT potency determination is a crucial step in basic research, in the development of pharmaceutical BoNTs, and in the quantitative detection of neutralizing antibodies.
Collapse
Affiliation(s)
- Sabine Pellett
- Department of Bacteriology, University of Wisconsin, Madison, WI 53706, USA.
| |
Collapse
|
7
|
Rzany B, Flynn TC, Schlöbe A, Heinz M, Harrington L. Long-term results for incobotulinumtoxinA in the treatment of glabellar frown lines. Dermatol Surg 2012. [PMID: 23190342 DOI: 10.1111/dsu.12008] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
BACKGROUND IncobotulinumtoxinA has been approved for treatment of glabellar frown lines (GFL) in the United States, all major European markets, South Korea, and Argentina and in Russia and Mexico for the treatment of mimic wrinkles and hyperkinetic facial lines, respectively. OBJECTIVES Prospective, 2-year, open-label, multicenter, repeat-dose, Phase III trial investigating the safety and efficacy of incobotulinumtoxinA for the treatment of GFL. METHODS Subjects with moderate or severe GFL on the Facial Wrinkle Scale (FWS), enrolled from previous trials, were treated with 20 U of incobotulinumtoxinA per cycle (up to eight treatment cycles, treatment interval at least 85 days). Efficacy was measured according to the investigator-assessed percentage of responders on the FWS (subjects with a score of 0 or 1) at rest and maximum frown on Day 30 of each cycle, subject assessments, and onset and duration of treatment effect. RESULTS In 796 subjects, 77% to 88% were responders at rest, and 79% to 90% were responders at maximum frown. Onset was rapid; subjects reported effects in the first few days after treatment. No new tolerability or safety concerns were reported. CONCLUSIONS IncobotulinumtoxinA injections were well tolerated and resulted in efficacy in the treatment of GFL for up to 2 years.
Collapse
Affiliation(s)
- Berthold Rzany
- Division of Evidence-Based Medicine, Klinik für Dermatologie, Charité Universitätsmedizin Berlin, Berlin, Germany.
| | | | | | | | | |
Collapse
|
8
|
Abstract
Botulinum toxin type A is a 150 kD protein produced by Clostridium botulinum, which exists in a complex with up to six additional proteins. The ability of botulinum toxin to inhibit acetylcholine release at the neuromuscular junction has been exploited for use in medical conditions characterized by muscle hyperactivity. As such, botulinum toxin is widely recommended by international treatment guidelines for movement disorders and it has a plethora of other clinical and cosmetic indications. The chronic nature of these conditions requires repeated injections of botulinum toxin, usually every few months. Multiple injections can lead to secondary treatment failure in some patients that may be associated with the production of neutralizing antibodies directed specifically against the neurotoxin. However, the presence of such antibodies does not always render patients non-responsive. The reported prevalence of immunoresistance varies greatly, depending on factors such as study design and treated indication. This review presents what is currently known about the immunogenicity of botulinum toxin and how this impacts upon patient non-response to treatment. The complexing proteins may act as adjuvants and stimulate the immune response. Their role and that of neutralizing and non-neutralizing antibodies in the response to botulinum toxin is discussed, together with an assessment of current neutralizing antibody measurement techniques. Botulinum toxin preparations with different compositions and excipients have been developed. The major commercially available preparations of botulinum toxin are Botox® (onabotulinumtoxinA; Allergan, Inc., Ireland), Dysport® (abobotulinumtoxinA; Ipsen Ltd, UK), and Xeomin® (incobotulinumtoxinA; botulinum toxin type A [150 kD], free from complexing proteins; NT 201; Merz Pharmaceuticals GmbH, Germany). The new preparations of botulinum toxin aim to minimize the risk of immunoresistance in patients being treated for chronic clinical conditions.
Collapse
Affiliation(s)
- Reiner Benecke
- Department of Neurology, University of Rostock, Rostock, Germany.
| |
Collapse
|
9
|
Kutschenko A, Reinert MC, Klinker F, Paulus W, Hesse S, Liebetanz D. Botulinum toxin-induced focal paresis in mice is unaffected by muscle activity. Muscle Nerve 2012; 44:930-6. [PMID: 22102464 DOI: 10.1002/mus.22210] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
INTRODUCTION To test the hypothesis that the efficacy of botulinum toxin depends on the activity of the neuromuscular junction, we developed an in vivo paradigm to determine the degree and duration of low-dose botulinum toxin-induced focal paresis in mice. METHODS We combined an automated wheel-running paradigm with low-dose botulinum toxin injections into the calf muscles of wild-type mice. Half of the mice were injected either before the nightly running or before the daily resting period. RESULTS After botulinum toxin injections, running distance and maximum velocity decreased dose-dependently. The degree and duration of decrease between the respective groups with regard to the time-points of injection were identical. CONCLUSIONS This in vivo paradigm quantifies the degree of otherwise clinically inapparent botulinum toxin-induced focal calf muscle paresis. Increased muscle activity after low-dose injections does not influence the efficacy of botulinum toxin in normal muscles.
Collapse
Affiliation(s)
- Anna Kutschenko
- Department of Clinical Neurophysiology, University Medical Centre Göttingen, Göttingen, Germany.
| | | | | | | | | | | |
Collapse
|
10
|
|
11
|
|
12
|
Dorner MB, Schulz KM, Kull S, Dorner BG. Complexity of Botulinum Neurotoxins: Challenges for Detection Technology. Curr Top Microbiol Immunol 2012. [DOI: 10.1007/978-3-662-45790-0_11] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
13
|
Kaynak-Hekimhan P. Noncosmetic periocular therapeutic applications of botulinum toxin. Middle East Afr J Ophthalmol 2011; 17:113-20. [PMID: 20616916 PMCID: PMC2892125 DOI: 10.4103/0974-9233.63069] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Botulinum toxin blocks acetylcholine release at the neuromuscular junction. The drug which was initially found to be useful in the treatment of strabismus has been extremely effective in the treatment of variety of conditions, both cosmetic and noncosmetic. Some of the noncosmetic uses of botulinum toxin applications include treatment of spastic facial dystonias, temporary treatment of idiopathic or thyroid dysfunction-induced upper eyelid retraction, suppression of undesired hyperlacrimation, induction of temporary ptosis by chemodenervation in facial paralysis, and correction of lower eyelid spastic entropion. Additional periocular uses include control of synchronic eyelid and extraocular muscle movements after aberrant regeneration of cranial nerve palsies. Cosmetic effects of botulinum toxin were discovered accidentally during treatments of facial dystonias. Some of the emerging nonperiocular application for the drug includes treatment of hyperhidrosis, migraine, tension-type headaches, and paralytic spasticity. Some of the undesired side effects of periocular applications of botulinum toxin inlcude ecchymosis, rash, hematoma, headache, flu-like symptoms, nausea, dizziness, loss of facial expression, lower eyelid laxity, dermatochalasis, ectropion, epiphora, eyebrow and eyelid ptosis, lagophthalmos, keratitis sicca, and diplopia.
Collapse
|
14
|
Phrenic nerve-hemidiaphragm as a highly sensitive replacement assay for determination of functional botulinum toxin antibodies. Toxicon 2011; 57:1008-16. [DOI: 10.1016/j.toxicon.2011.04.003] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2010] [Revised: 04/01/2011] [Accepted: 04/05/2011] [Indexed: 12/14/2022]
|
15
|
Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing? Clin Neuropharmacol 2009; 32:213-8. [PMID: 19620852 DOI: 10.1097/wnf.0b013e3181914d0a] [Citation(s) in RCA: 106] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVES As the indications and duration of treatment of botulinum toxin type A (BoNT-A) increase, so do reports of patients who fail therapy after initially responding well. Although a loss of efficacy is commonly thought to be associated with neutralizing antibodies (NAbs), this relationship is not strongly correlated, and other factors may play a significant role. To explore this issue, we evaluated levels of NAbs in a large selected cohort of secondary nonresponders to BoNT-A using the highly sensitive mouse phrenic nerve-hemidiaphragm assay. METHODS Serum samples from 503 patients treated with BoNT-A who had a variety of diagnoses were tested for the presence of NAbs. RESULTS Fewer than half of the patients (n = 224, 44.5%) were found to be NAb-positive, indicating that in more than half of the secondary nonresponders, lack of efficacy is not due to NAb formation. The proportion of secondary nonresponders with NAbs was greater for higher dose indications (focal spasticity and spasmodic torticollis) than for lower dose indications (blepharospasm and hemifacial spasm) and increased with shorter injection intervals. Neutralizing antibody development was independent of the commercial preparation used. CONCLUSIONS Our results indicate that although NAb formation does play a role in secondary treatment failure with BoNT-A, this is not the cause in all patients, and the influence of other factors needs to be investigated. Gaining a better understanding of the underlying mechanisms for secondary treatment failure may help in the prediction, diagnosis, management, and prevention of this problem.
Collapse
|
16
|
Rasetti-Escargueil C, Jones RGA, Liu Y, Sesardic D. Measurement of botulinum types A, B and E neurotoxicity using the phrenic nerve-hemidiaphragm: improved precision with in-bred mice. Toxicon 2009; 53:503-11. [PMID: 19673096 DOI: 10.1016/j.toxicon.2009.01.019] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Botulinum neurotoxins induce a prolonged muscle paralysis by specifically blocking the release of neuronal transmitters from peripheral nerve junctions. The current method for assessing the potency of botulinum toxin and antitoxins is the mouse LD50 assay. The mouse phrenic nerve-diaphragm assay is an in vitro assay that closely mimics in vivo respiratory paralysis. In this study, we have further improved the assay by using gelatin as a non-frothing alternative to albumin and investigated the effects of botulinum toxin serotypes A, B and E on phrenic nerve-hemidiaphragms from out-bred MF1 and in-bred Balb/c mice. Improved reproducibility was found with in-bred mice. Balb/c mice were also found to be much less sensitive to type B toxin perhaps indicating differences in the expression of receptor components. Hemidiaphragm preparations from Balb/c mice were approximately 7 times more sensitive to type A toxin and 7-12 times more sensitive to type E toxin relative to type B toxin. These findings indicate that when fully optimised the mouse nerve-diaphragm preparation can provide a functional in vitro model for accurate and reproducible assessment of toxin activity.
Collapse
Affiliation(s)
- C Rasetti-Escargueil
- Division of Bacteriology, National Institute for Biological Standards and Control Blanche Lane, South Mimms, Potters Bar, Hertfordshire, EN6 3QG, UK.
| | | | | | | |
Collapse
|
17
|
Bachhuber A, Reichel G, Doberenz M, Stenner A, Hermann W. Botulinum-Toxin-Behandlung. DER NERVENARZT 2009; 80:712-6. [DOI: 10.1007/s00115-009-2690-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
18
|
Bachhuber A, Wagner A, Reichel G, Doberenz M, Stenner A, Hermann W. Nachweis von Botulinum-Toxin-Antikörper. DER NERVENARZT 2008; 79:908-11. [DOI: 10.1007/s00115-008-2470-x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
19
|
Abstract
Cervical dystonia (CD) is the most common form of focal dystonia treated with botulinum toxin (BoNT) injections. BoNT has been shown in numerous clinical trials to correct the abnormal posture and movement and to markedly reduce pain associated with CD. In addition, BoNT has favorably modified the natural history of the disease by preventing contractures and other complications of CD, such as secondary degenerative changes of the cervical spine and associated radiculopathy. In a long-term follow-up of patients treated for up to 20 years, the duration of response appears to be sustained and the risk of immunoresistance due to blocking antibodies is relatively small. This review provides and update on the treatment of CD with BoNT type A (BOTOX, Dysport, Xeomin and BoNT type B (Myobloc, NeuroBloc.
Collapse
Affiliation(s)
- J Jankovic
- Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA.
| |
Collapse
|
20
|
Abstract
BACKGROUND Cervical dystonia results in severe disability and cannot be effectively treated with medication. Repeat injections of botulinum toxin into the dystonic neck muscles can relieve the symptoms in most patients. When this treatment fails (mostly due to antibody formation), deep brain stimulation can be considered. PATIENTS AND METHODS We report our experiences with eight patients who were treated with bilateral deep brain stimulation of the globus pallidus interna for cervical dystonia. The mean observation period was 31 months. RESULTS Six of eight patients experienced relief from symptoms a few days after the implantation. Improvement of symptoms was a mean of 60% during the 1st year. There were no complications. CONCLUSION In this and in other studies with small numbers of patients, deep brain stimulation has shown a good effect on cervical dystonia. According to our results, the patients who benefit most are those with no dystonic shoulder involvement and who have a tonic rather than clonic symptomatology. It seems probable that deep brain stimulation will become the therapy of choice for otherwise intractable cervical dystonia.
Collapse
Affiliation(s)
- K Bötzel
- Neurologische Klinik der Ludwig-Maximilians-Universität, Klinikum Grosshadern, 81377 München.
| | | |
Collapse
|